GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Debt-to-Equity

Cantargia AB (FRA:7V3) Debt-to-Equity : 0.00 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Debt-to-Equity?

Cantargia AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Cantargia AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Cantargia AB's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €10.11 Mil. Cantargia AB's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cantargia AB's Debt-to-Equity or its related term are showing as below:

FRA:7V3's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cantargia AB Debt-to-Equity Historical Data

The historical data trend for Cantargia AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Debt-to-Equity Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cantargia AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cantargia AB's Debt-to-Equity

For the Biotechnology subindustry, Cantargia AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Debt-to-Equity falls into.


;
;

Cantargia AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cantargia AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Cantargia AB's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB  (FRA:7V3) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Cantargia AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines